Page 17 - Read Online

Page 4 of 4 Waheed et al. Hepatoma Res 2018;4:45 I http://dx.doi.org/10.20517/2394-5079.2018.58

2015;109:353.
3. World Health Organization. Global Health Sector Strategies on Viral Hepatitis 2016-2021. Published 22 April 2016. Available from:
http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1. [Last accessed on 9 Aug 2018]
4. Polaris Observatory HCV collaborators. Global prevalence and genotype distribution of hepatitis C infection in 2015: a modelling study.
Lancet Gastroenterol Hepatol 2017;2:161-76.
5. World Health Organization. Progress report on access to hepatitis C treatment, focus on overcoming barriers in low and middle income
countries. Published March 2018. Available from: http://apps.who.int/iris/bitstream/10665/260445/1/WHO-CDS-HIV-18.4-eng.
pdf?ua=1. [Last accessed on 9 Aug 2018]
6. Polaris Observatory. Center for Disease Analysis. Available from: http://cdafound.org/polaris/. [Last accessed on 9 Aug 2018]
7. National Hepatitis Strategic Framework for Pakistan (2017-2021). Available from: http://phrc.org.pk/Extra/NHSF.pdf. [Last accessed on
9 Aug 2018]
8. Waheed Y, Shafi T, Safi, SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World
J Gastroenterology 2009;15:5647-53.
9. Aziz H, Ather MA, Murtaza S, Irafan J, Waheed Y, Bilal I. Predictors of response to antiviral therapy in patients with chronic hepatitis C
from Pakistani population. Chin Med J 2011;124:1333-7.
10. Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I, Athar MA. Evaluation of prognostic factors for peg interferon alfa-2b plus
ribavirin treatment on HCV infected patients in Pakistan. Infect Genet Evol 2011;11:640-5.
11. Aziz H, Raza A, Waheed Y, Gill U, Gil ML. Analysis of variables and interactions among variables associated with a sustained
virological response to pegylated interferon alpha 2a plus ribavirin in hepatitis C virus genotype 3 infected patients. Int J Infect Dis
2012;16:e597-602.
12. Jamil Z, Waheed Y, Malik M, Durrani AA. Effect of sofosuvir plus ribavirin therapy on hepatitis C patients in Pakistan: a retrospective
study. Peer J 2018;6:e4853.
13. Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickery A, Glass N, Saeed Q, Fraser H, Walker JG, Mukandavire C, Hickman M,
Martin NK, May MT, Averhoff F, Vickerman P. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment
and prevention for achieving elimination. Int J Epidemiology 2018; doi: 10.1093/ije/dyx270.
14. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national
survey appealing for efeective prevention and control measures. East Mediterr Health J 2010;16:S15-23.
15. Saeed U, Waheed Y, Ashraf M, Waheed U, Anjum S, Afzal MS. Estimation of hepatitis B virus, hepatitis C virus, and different clinical
parameters in the thalaseemic population of capital twin cities of Pakistan. Virology (Auckl) 2015;6:11-6.
16. Waheed Y, Najmi MH, Aziz H, Waheed H, Imran M, Safi SZ. Prevalence of hepatitis C in people who inject drugs in the cities of
Rawalpindi and Islamabad, Pakistan. Biomed Rep 2017;7:263-6.
17. Omran H. World Bank to lend Health Ministry $200m for hepatitis C screening: minister. Available from: https://dailynewsegypt.
com/2018/03/28/world-bank-lend-health-ministry-200m-hepatitis-c-screening-minister/. [Last accessed on 9 Aug 2018]
18. Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A,
Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer
H, Yazdanpanah Y, Zuure F, Manns MP. Hepatitis C: the beginning of the end-key elements for successful European and national
strategies to eliminate HCV in Europe. J Viral Hepatitis 2018;Suppl 1:6-17.
19. Waheed Y. Hepatitis C eradication: a long way to go. World J Gastroenterol 2015;21:12510-2.